We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
LifeSpan and MBL Announce Multi-Year Licensing and Asset Agreement
News

LifeSpan and MBL Announce Multi-Year Licensing and Asset Agreement

LifeSpan and MBL Announce Multi-Year Licensing and Asset Agreement
News

LifeSpan and MBL Announce Multi-Year Licensing and Asset Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "LifeSpan and MBL Announce Multi-Year Licensing and Asset Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

LifeSpan BioSciences, Inc. and MBL International Corporation, a wholly owned subsidiary of Medical and Biological Laboratories Co., Ltd. (Nagoya, Japan), have announced a multi-year relationship in which MBLI will distribute antibodies to druggable gene targets that LifeSpan has developed and commercialized.

As part of the new relationship, MBLI has purchased LifeSpan’s existing inventory of 900 antibodies including the exclusive research reagent sales rights.

Dennis Walczewski, chief executive officer of MBLI said, "The relationship with LifeSpan addresses the needs of both organizations."

"The products and technology obtained from LifeSpan complement our existing product lines, increasing our product offering to over 4,000 products. LifeSpan and MBLI feel that this relationship will help both companies meet the future needs of the scientific research community."

Dr. Joseph Brown, president and CEO of LifeSpan said, "This partnership with MBLI is an important milestone in LifeSpan’s long term strategy to become a global provider of Molecular Pathology products and services, including reagent antibodies to the genes most important in finding new treatments for disease."

"Moreover, it gives LifeSpan new resources to fund additional development within our core business."

Advertisement